* If you want to update the article please login/register
Chimeric antigen receptor T-cells have the potential to be a major innovation as a new type of cancer treatment, however are linked with very high rates and a high level of unpredictability. This study intends to analyze the price of the healthcare facility remain for the administration of anti-CD19 CAR-T cells in France. 485 health center stays associated with an injection of anti-CD19 CAR-T cells were determined, of which 44, 139, and 302 were for tisagenlecleucel in acute lymphoblastic leukaemia, tisagenlecleucel in diffuse huge B-cell lymphoma, and axicabtagene ciloleucel specifically. The mean costs per medical facility remain were EUR 372,400 for a tisagenlecleucel in ALL, EUR 342,903 for tisagenlecleucel in DLBCL, and EUR 366,562 for axicabtagene ciloleucel. Along with the financial problem, distance may also be a crucial obstacle for accessing CAR T-cell treatment.
Source link: https://europepmc.org/article/MED/34561025
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions